RxDoctor Payments Data

Brian Pearlman, MD

Internal Medicine · Dalton, GANPI 1528068384

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $148,055 of the $198,558 with a category attached, or 74.6%. 20 manufacturers reported payments, led by Gilead at 49.8% of the total. Reporting peaked in 2019 at $94,584 and has fallen 86.8% since, to $12,505 in 2025. Among internal medicine clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$198,558in general payments, 2019–2025

Across 263 payments — averaging $754.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$99K
  • AbbVie$89K
  • Mallinckrodt Hospital Products Inc.$6K
  • Ipsen Biopharmaceuticals, Inc$1K
  • Novo Nordisk$1K
  • Siemens Medical Solutions USA, Inc.$1K
  • plus $422 from 14 others
$139,600in research payments, 2019–2025

Across 23 payments — averaging $6069.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$105K
  • Gilead$27K
  • AbbVie$8K

What the payments were for

  • Consulting fees$20,16810%
  • Speaking & faculty fees$148,05575%
  • Travel & lodging$25,39613%
  • Food & beverage$4,9392%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$198,558 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$17,583
Medicare patients
86
Services billed
193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban16$9,911
Losartan Potassium13$210
Atorvastatin Calcium17$91
Amlodipine Besylate11$84
Lisinopril14$75

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$128$9,91116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Dalton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →